Related references
Note: Only part of the references are listed.A new automated method to assess the rat recognition memory: Validation of the method
Caroline Chambon et al.
BEHAVIOURAL BRAIN RESEARCH (2011)
Behavioral effects of PNU-282987, an alpha7 nicotinic receptor agonist, in mice
Paloma Vicens et al.
BEHAVIOURAL BRAIN RESEARCH (2011)
Immediate and Sustained Improvements in Working Memory After Selective Stimulation of alpha 7 Nicotinic Acetylcholine Receptors
Stacy A. Castner et al.
BIOLOGICAL PSYCHIATRY (2011)
Effects of an Alpha 7-Nicotinic Agonist on Default Network Activity in Schizophrenia
Jason R. Tregellas et al.
BIOLOGICAL PSYCHIATRY (2011)
Insights into the neurodevelopmental origin of schizophrenia from postmortem studies of prefrontal cortical circuitry
Monica Beneyto et al.
INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE (2011)
RG3487, a Novel Nicotinic alpha 7 Receptor Partial Agonist, Improves Cognition and Sensorimotor Gating in Rodents
Tanya L. Wallace et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
A randomized double-blind study comparing 25 and 50 mg TC-1734 (AZD3480) with placebo, in older subjects with age-associated memory impairment
Geoffrey C. Dunbar et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2011)
Modes and Models of Forebrain Cholinergic Neuromodulation of Cognition
Michael E. Hasselmo et al.
NEUROPSYCHOPHARMACOLOGY (2011)
Activation of nicotinic α7 acetylcholine receptor enhances long term potentation in wild type mice but not in APPswe/PS1ΔE9 mice
Andreas Soderman et al.
NEUROSCIENCE LETTERS (2011)
Discovery and Characterization of Novel Subtype-Selective Allosteric Agonists for the Investigation of M1 Receptor Function in the Central Nervous System
Evan P. Lebois et al.
ACS CHEMICAL NEUROSCIENCE (2010)
The enhancement of contextual fear conditioning by ABT-418
Justin W. Kenney et al.
BEHAVIOURAL PHARMACOLOGY (2010)
Heterobiaryl and heterobiaryl ether derived M5 positive allosteric modulators
Thomas M. Bridges et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2010)
Continuous administration of a selective α7 nicotinic partial agonist, DMXBA, improves sensory inhibition without causing tachyphylaxis or receptor upregulation in DBA/2 mice
Karen E. Stevens et al.
BRAIN RESEARCH (2010)
Distinct Neural Pathways Mediate α7 Nicotinic Acetylcholine Receptor-Dependent Activation of the Forebrain
Morten S. Thomsen et al.
CEREBRAL CORTEX (2010)
Treating the Cognitive Deficits of Schizophrenia with Alpha4Beta2 Neuronal Nicotinic Receptor Agonists
Richard J. Radek et al.
CURRENT PHARMACEUTICAL DESIGN (2010)
Structural Determinants of Allosteric Agonism and Modulation at the M4 Muscarinic Acetylcholine Receptor IDENTIFICATION OF LIGAND-SPECIFIC AND GLOBAL ACTIVATION MECHANISMS
Vindhya Nawaratne et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Differential Regulation of alpha 7 Nicotinic Receptor Gene (CHRNA7) Expression in Schizophrenic Smokers
Sharon Mexal et al.
JOURNAL OF MOLECULAR NEUROSCIENCE (2010)
A Subpopulation of Neuronal M4 Muscarinic Acetylcholine Receptors Plays a Critical Role in Modulating Dopamine-Dependent Behaviors
Jongrye Jeon et al.
JOURNAL OF NEUROSCIENCE (2010)
The M1 Muscarinic Receptor Allosteric Agonists AC-42 and 1-[1′-(2-Methylbenzyl)-1,4′-bipiperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one Bind to a Unique Site Distinct from the Acetylcholine Orthosteric Site
Marlene A. Jacobson et al.
MOLECULAR PHARMACOLOGY (2010)
Orthosteric and Allosteric Modes of Interaction of Novel Selective Agonists of the M1 Muscarinic Acetylcholine Receptor
Vimesh A. Avlani et al.
MOLECULAR PHARMACOLOGY (2010)
Muscarinic receptors induce LTD of NMDAR EPSCs via a mechanism involving hippocalcin, AP2 and PSD-95
Jihoon Jo et al.
NATURE NEUROSCIENCE (2010)
Facilitation of Long-Term Potentiation by Muscarinic M1 Receptors Is Mediated by Inhibition of SK Channels
Katherine A. Buchanan et al.
NEURON (2010)
AC-260584, an orally bioavailable M1 muscarinic receptor allosteric agonist, improves cognitive performance in an animal model
Stefania Risso Bradley et al.
NEUROPHARMACOLOGY (2010)
Investigation into the efficacy of the acetylcholinesterase inhibitor, donepezil, and novel procognitive agents to induce gamma oscillations in rat hippocampal slices
J. P. Spencer et al.
NEUROPHARMACOLOGY (2010)
Molecular Mechanisms of Action and In Vivo Validation of an M4 Muscarinic Acetylcholine Receptor Allosteric Modulator with Potential Antipsychotic Properties
Katie Leach et al.
NEUROPSYCHOPHARMACOLOGY (2010)
Functional Magnetic Resonance Imaging of Effects of a Nicotinic Agonist in Schizophrenia
Jason R. Tregellas et al.
NEUROPSYCHOPHARMACOLOGY (2010)
The M3-muscarinic receptor regulates learning and memory in a receptor phosphorylation/arrestin-dependent manner
Benoit Poulin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Varenicline and P50 auditory gating in medicated schizophrenic patients: A pilot study
Merilyne C. Waldo et al.
PSYCHIATRY RESEARCH (2010)
TOXIC EFFECT OF SCOPOLAMINE EYE DROPS IN CHILDREN
B. HAMBORG-PETERSEN et al.
ACTA OPHTHALMOLOGICA (2009)
Evaluation of α7 Nicotinic Acetylcholine Receptor Agonists and Positive Allosteric Modulators Using the Parallel Oocyte Electrophysiology Test Station
John Malysz et al.
ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES (2009)
Stimulation of dopamine release by nicotinic acetylcholine receptor ligands in rat brain slices correlates with the profile of high, but not low, sensitivity α4β2 subunit combination
David J. Anderson et al.
BIOCHEMICAL PHARMACOLOGY (2009)
A reversible model of the cognitive impairment associated with schizophrenia in monkeys: Potential therapeutic effects of two nicotinic acetylcholine receptor agonists
Jerry J. Buccafusco et al.
BIOCHEMICAL PHARMACOLOGY (2009)
Selective α7 nicotinic receptor activation by AZD0328 enhances cortical dopamine release and improves learning and attentional processes
Simon Sydserff et al.
BIOCHEMICAL PHARMACOLOGY (2009)
nAChR agonist-induced cognition enhancement: Integration of cognitive and neuronal mechanisms
Martin Sarter et al.
BIOCHEMICAL PHARMACOLOGY (2009)
TC-5619: An alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia
T. A. Hauser et al.
BIOCHEMICAL PHARMACOLOGY (2009)
Positive allosteric modulation of α7 neuronal nicotinic acetylcholine receptors: lack of cytotoxicity in PC12 cells and rat primary cortical neurons
Min Hu et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
Pentameric concatenated (α4)2(β2)3 and (α4)3(β2)2 nicotinic acetylcholine receptors: subunit arrangement determines functional expression
A-L Carbone et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
Pharmacological comparison of muscarinic ligands: Historical versus more recent muscarinic M1-preferring receptor agonists
Julia N. Heinrich et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2009)
α7 nicotinic acetylcholine receptor activation ameliorates scopolamine-induced behavioural changes in a modified continuous Y-maze task in mice
John R. Redrobe et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2009)
Discovery of 4-(5-(4-Chlorophenyl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide (A-867744) as a Novel Positive Allosteric Modulator of the α7 Nicotinic Acetylcholine Receptor
Ramin Faghih et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Discovery of the First Highly M5-Preferring Muscarinic Acetylcholine Receptor Ligand, an M5 Positive Allosteric Modulator Derived from a Series of 5-Trifluoromethoxy N-Benzyl Isatins
Thomas M. Bridges et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
The muscarinic M1 receptor activates Nrf2 through a signaling cascade that involves protein kinase C and inhibition of GSK-3beta: connecting neurotransmission with neuroprotection
Sandra Espada et al.
JOURNAL OF NEUROCHEMISTRY (2009)
A Selective Allosteric Potentiator of the M1 Muscarinic Acetylcholine Receptor Increases Activity of Medial Prefrontal Cortical Neurons and Restores Impairments in Reversal Learning
Jana K. Shirey et al.
JOURNAL OF NEUROSCIENCE (2009)
Desensitization of Nicotinic Acetylcholine Receptors as a Strategy for Drug Development
Jerry J. Buccafusco et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
M-5 Muscarinic Receptor Knockout Mice Show Reduced Morphine-Induced Locomotion but Increased Locomotion after Cholinergic Antagonism in the Ventral Tegmental Area
Stephan Steidl et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
Procognitive and Neuroprotective Activity of a Novel α7 Nicotinic Acetylcholine Receptor Agonist for Treatment of Neurodegenerative and Cognitive Disorders
Renza Roncarati et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
Discovery and Characterization of Novel Allosteric Potentiators of M1 Muscarinic Receptors Reveals Multiple Modes of Activity
Joy E. Marlo et al.
MOLECULAR PHARMACOLOGY (2009)
Decreased cortical muscarinic receptors define a subgroup of subjects with schizophrenia
E. Scarr et al.
MOLECULAR PSYCHIATRY (2009)
Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders
P. Jeffrey Conn et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
alpha(7) Nicotinic acetylcholine receptor activation prevents behavioral and molecular changes induced by repeated phencyclidine treatment
Morten S. Thomsen et al.
NEUROPHARMACOLOGY (2009)
Nicotine-induced plasticity during development: Modulation of the cholinergic system and long-term consequences for circuits involved in attention and sensory processing
Christopher J. Heath et al.
NEUROPHARMACOLOGY (2009)
Pro-Cognitive and Antipsychotic Efficacy of the α7 Nicotinic Partial Agonist SSR180711 in Pharmacological and Neurodevelopmental Latent Inhibition Models of Schizophrenia
Segev Barak et al.
NEUROPSYCHOPHARMACOLOGY (2009)
Mammalian Nicotinic Acetylcholine Receptors: From Structure to Function
Edson X. Albuquerque et al.
PHYSIOLOGICAL REVIEWS (2009)
Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation
Lei Ma et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Effect of R3487/MEM3454, a novel nicotinic α7 receptor partial agonist and 5-HT3 antagonist on sustained attention in rats
Amir H. Rezvani et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2009)
The Dopamine Hypothesis of Schizophrenia: Version III - The Final Common Pathway
Oliver D. Howes et al.
SCHIZOPHRENIA BULLETIN (2009)
Prepulse inhibition deficits in schizophrenia are modified by smoking status
Andrea A. Woznica et al.
SCHIZOPHRENIA RESEARCH (2009)
Correlation of prepulse inhibition and Wisconsin Card Sorting Test in schizophrenia and controls: Effects of smoking status
Rachel A. Rabin et al.
SCHIZOPHRENIA RESEARCH (2009)
Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder
Robert C. Smith et al.
SCHIZOPHRENIA RESEARCH (2009)
Weight effects associated with antipsychotics: A comprehensive database analysis
Bruce Parsons et al.
SCHIZOPHRENIA RESEARCH (2009)
Initial phase 2 trial of a nicotinic agonist in schizophrenia
Robert Freedman et al.
AMERICAN JOURNAL OF PSYCHIATRY (2008)
Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia
Anantha Shekhar et al.
AMERICAN JOURNAL OF PSYCHIATRY (2008)
Antipsychotic-like behavioral effects and cognitive enhancement by a potent and selective muscarinic M-1 receptor agonist, AC-260584
Kimberly E. Vanover et al.
BEHAVIORAL NEUROSCIENCE (2008)
Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the novel selective alpha 7 nicotinic receptor agonist SSR180711
Kenji Hashimoto et al.
BIOLOGICAL PSYCHIATRY (2008)
Stimulation of the α4β2 nicotinic receptor by 5-I A-85380 improves auditory gating in DBA/2 mice
Kristin M. Wildeboer et al.
BRAIN RESEARCH (2008)
Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77-LH-28-1
C. J. Langmead et al.
BRITISH JOURNAL OF PHARMACOLOGY (2008)
Functional selectivity in GPCR modulator screening
Terry Kenakin
COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING (2008)
FDA warns of adverse events linked to smoking cessation drug and antiepileptics
Bridget M. Kuehn
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Genetic association analysis of tagging SNPs in alpha4 and beta2 subunits of neuronal nicotinic acetylcholine receptor genes (CHRNA4 and CHRNB2) with schizophrenia in the Japanese population
Taro Kishi et al.
JOURNAL OF NEURAL TRANSMISSION (2008)
Novel Selective Allosteric Activator of the M1 Muscarinic Acetylcholine Receptor Regulates Amyloid Processing and Produces Antipsychotic-Like Activity in Rats
Carrie K. Jones et al.
JOURNAL OF NEUROSCIENCE (2008)
Centrally Active Allosteric Potentiators of the M4 Muscarinic Acetylcholine Receptor Reverse Amphetamine-Induced Hyperlocomotor Activity in Rats
Ashley E. Brady et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Large recurrent microdeletions associated with schizophrenia
Hreinn Stefansson et al.
NATURE (2008)
The partial α7 nicotine acetylcholine receptor agonist S 24795 enhances long-term potentiation at CA3-CA1 synapses in the adult mouse hippocampus
Laura Lagostena et al.
NEUROPHARMACOLOGY (2008)
Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia
W. Y. Chan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
It is not either/or: Activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood
Marina R. Picciotto et al.
PROGRESS IN NEUROBIOLOGY (2008)
What CATIE found: Results from the schizophrenia trial
Marvin S. Swartz et al.
PSYCHIATRIC SERVICES (2008)
Effects of transdermal nicotine on episodic memory in non-smokers with and without schizophrenia
Lindsay E. Jubelt et al.
PSYCHOPHARMACOLOGY (2008)
Early nicotine withdrawal and transdermal nicotine effects on neurocognitive performance in schizophrenia
Christopher G. AhnAllen et al.
SCHIZOPHRENIA RESEARCH (2008)
Early onset of antipsychotic response in the treatment of acutely agitated patients with psychotic disorders
Ofer Agid et al.
SCHIZOPHRENIA RESEARCH (2008)
The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls
Ruth S. Barr et al.
NEUROPSYCHOPHARMACOLOGY (2008)
An allosteric potentiator of M-4 mAChR modulates hippocampal synaptic transmission
Jana K. Shirey et al.
NATURE CHEMICAL BIOLOGY (2008)
AC260584 (4-[3-(4-butylpiperidin-1-yl)-propyl]-7-fluoro-4H-benzo[1,4] oxazin-3-one), a selective muscarinic M1 receptor agonist, increases acetylcholine and dopamine release in rat medial prefrontal cortex and hippocampus
Zhu Li et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2007)
Profile of nicotinic acetylcholine receptor agonists ABT-594 and A-582941, with differential subtype selectivity, on delayed matching accuracy by young monkeys
Jerry J. Buccafusco et al.
BIOCHEMICAL PHARMACOLOGY (2007)
An allosteric modulator of the α7 nicotinic acetylcholine receptor possessing cognition-enhancing properties in vivo
Daniel B. Timmermann et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
The effects of JWB1-84-1 on memory-related task performance by amyloid Aβ transgenic mice and by young and aged monkeys
Ajay Sood et al.
NEUROPHARMACOLOGY (2007)
Broad-spectrum efficacy across cognitive domains by α7 nicotinic acetylcholine receptor agonism correlates with activation of ERK1/2 and CREB phosphorylation pathways
Robert S. Bitner et al.
JOURNAL OF NEUROSCIENCE (2007)
Distinct profiles of α7 nAChR positive allosteric modulation revealed by structurally diverse chemotypes
Jens Halvard Gronlien et al.
MOLECULAR PHARMACOLOGY (2007)
Evaluation of N-desmethylclozapine as a potential antipsychotic -: Preclinical studies
Sridhar Natesan et al.
NEUROPSYCHOPHARMACOLOGY (2007)
Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: A randomized, double-blind 52-week comparison
Richard S. E. Keefe et al.
AMERICAN JOURNAL OF PSYCHIATRY (2007)
Alpha-7 nicotinic acetylcholine receptor agonists selectively activate limbic regions of the rat forebrain: An effect similar to antipsychotics
Henrik H. Hansen et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2007)
Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study
Howard H. Feldman et al.
LANCET NEUROLOGY (2007)
Frontal cortical α7 and α4β2 nicotinic acetylcholine receptors in working and reference memory
Wai Kit Chan et al.
NEUROPHARMACOLOGY (2007)
Nootropic α7 nicotinic receptor allosteric modulator derived from GABAA receptor modulators
Herman J. Ng et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
The novel α7 nicotinic acetylcholine receptor agonist N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2-carboxamide improves working and recognition memory in rodents
Frank G. Boess et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
Decreased prepulse inhibition and increased sensitivity to muscarinic, but not dopaminergic drugs in M5 muscarinic acetylcholine receptor knockout mice
Morgane Thomsen et al.
PSYCHOPHARMACOLOGY (2007)
Ca2+ permeability of the (α4)3(β2)2 stoichiometry greatly exceeds that of (α4)2(β2)3 human acetylcholine receptors
L. Tapia et al.
MOLECULAR PHARMACOLOGY (2007)
Early onset of treatment effects with oral risperidone
Thomas J. Raedler et al.
BMC PSYCHIATRY (2007)
SSR180711, a novel selective α7 nicotinic receptor partial agonist:: (I) binding and functional profile
Bruno Biton et al.
NEUROPSYCHOPHARMACOLOGY (2007)
SSR180711, a novel selective alpha 7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia
Philippe Pichat et al.
NEUROPSYCHOPHARMACOLOGY (2007)
Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development
Juergen Wess et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Loss of M5 muscarinic acetylcholine receptors leads to cerebrovascular and neuronal abnormalities and cognitive deficits in mice
Runa Araya et al.
NEUROBIOLOGY OF DISEASE (2006)
Sazetidine-a, a novel ligand that desensitizes α4β2 nicotinic acetylcholine receptors without activating them
Yingxian Xiao et al.
MOLECULAR PHARMACOLOGY (2006)
Cognitive dysfunction in schizophrenia -: Convergence of γ-aminobutyric acid and glutamate alterations
David A. Lewis et al.
ARCHIVES OF NEUROLOGY (2006)
A preliminary study of the effects of cigarette smoking on prepulse inhibition in schizophrenia: Involvement of nicotinic receptor mechanisms
Tony P. George et al.
SCHIZOPHRENIA RESEARCH (2006)
Varenicline is a partial agonist at α4β2 and a full agonist at α7 neuronal nicotinic receptors
Karla B. Mihalak et al.
MOLECULAR PHARMACOLOGY (2006)
Genetic interaction between α4 and β2 subunits of high affinity nicotinic receptor:: analysis in schizophrenia
Vincenzo De Luca et al.
EXPERIMENTAL BRAIN RESEARCH (2006)
Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the α7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia:: Synthesis and structure-activity relationship
Donn G. Wishka et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Neuropsychological deficits in nonsmokers with schizophrenia: Effects of a nicotinic antagonist
Kristi A. Sacco et al.
SCHIZOPHRENIA RESEARCH (2006)
Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder
Paul Abrams et al.
BRITISH JOURNAL OF PHARMACOLOGY (2006)
Proof-of-concept trial of an α7 nicotinic agonist in schizophrenia
Ann Olincy et al.
ARCHIVES OF GENERAL PSYCHIATRY (2006)
Smoking is associated with schizophrenia, but not with mood disorders, within a population with low smoking rates:: A matched case-control study in Bucaramanga, Colombia
A Campo-Arias et al.
SCHIZOPHRENIA RESEARCH (2006)
Effects of nicotine nasal spray on cognitive function in schizophrenia
RC Smith et al.
NEUROPSYCHOPHARMACOLOGY (2006)
Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization
ED Levin et al.
PSYCHOPHARMACOLOGY (2006)
Activation of alpha 7 acetylcholine receptors augments stimulation-induced hippocampal theta oscillation
CJ Siok et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2006)
Augmented prefrontal acetylcholine release during challenged attentional performance
R Kozak et al.
CEREBRAL CORTEX (2006)
Preliminary observations of oral nicotine therapy for inflammatory bowel disease: An open-label phase I-II study of tolerance
JR Ingram et al.
INFLAMMATORY BOWEL DISEASES (2005)
Decreased density of muscarinic receptors in the superior temporal gyrus in schizophrenia
C Deng et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2005)
Early-onset hypothesis of antipsychotic drug action: A hypothesis tested, confirmed and extended
S Leucht et al.
BIOLOGICAL PSYCHIATRY (2005)
Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia - Involvement of nicotinic receptor mechanisms
KA Sacco et al.
ARCHIVES OF GENERAL PSYCHIATRY (2005)
Evidence for onset of antipsychotic effects within the first 24 hours of treatment
S Kapur et al.
AMERICAN JOURNAL OF PSYCHIATRY (2005)
A novel positive allosteric modulator of the α7 neuronal nicotinic acetylcholine receptor:: In vitro and in vivo characterization
RS Hurst et al.
JOURNAL OF NEUROSCIENCE (2005)
Pharmacologic interactions between the muscarinic cholinergic and dopaminergic systems in the modulation of prepulse inhibition in rats
CK Jones et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
AR-R 17779 improves social recognition in rats by activation of nicotinic α7 receptors
M van Kampen et al.
PSYCHOPHARMACOLOGY (2004)
Investigation of M1/M4 muscarinic receptors in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression disorder
Z Katerina et al.
NEUROPSYCHOPHARMACOLOGY (2004)
Effects of nicotinic stimulation on cognitive performance
PA Newhouse et al.
CURRENT OPINION IN PHARMACOLOGY (2004)
M1 receptor agonism, a possible treatment for cognitive deficits in schizophrenia
K Zavitsanou
NEUROPSYCHOPHARMACOLOGY (2004)
Identification of separable cognitive factors in schizophrenia
KH Nuechterlein et al.
SCHIZOPHRENIA RESEARCH (2004)
Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS
MF Green et al.
SCHIZOPHRENIA RESEARCH (2004)
Neuronal nicotinic receptors: from structure to pathology
C Gotti et al.
PROGRESS IN NEUROBIOLOGY (2004)
Effects of nicotine on cognitive deficits in schizophrenia
JG Harris et al.
NEUROPSYCHOPHARMACOLOGY (2004)
M2 muscarinic acetylcholine receptor knock-out mice show deficits in behavioral flexibility, working memory, and hippocampal plasticity
T Seeger et al.
JOURNAL OF NEUROSCIENCE (2004)
Linkage of M5 muscarinic and alpha 7-nicotinic receptor genes on 15q13 to schizophrenia
V De Luca et al.
NEUROPSYCHOBIOLOGY (2004)
Physiological roles of neuronal nicotinic receptor subtypes: New insights on the nicotinic modulation of neurotransmitter release, synaptic transmission and plasticity
E Sher et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2004)
Novel insights into M5 muscarinic acetylcholine receptor function by the use of gene targeting technology
M Yamada et al.
LIFE SCIENCES (2003)
Delayed-onset hypothesis of antipsychotic action - A hypothesis tested and rejected
O Agid et al.
ARCHIVES OF GENERAL PSYCHIATRY (2003)
N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity
C Sur et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Role for M5 muscarinic acetylcholine receptors in cocaine addiction
A Fink-Jensen et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2003)
Novel modulatory mechanisms revealed by the sustained application of nicotine in the guinea-pig hippocampus in vitro
EO Mann et al.
JOURNAL OF PHYSIOLOGY-LONDON (2003)
Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: A randomized, double-blind trial of olanzapine versus haloperidol
JA Lieberman et al.
AMERICAN JOURNAL OF PSYCHIATRY (2003)
Attentional effects of nicotinic agonists in rats
B Hahn et al.
NEUROPHARMACOLOGY (2003)
Reduced expression of the muscarinic 1 receptor cortical subtype in schizophrenia
D Mancama et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS (2003)
Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers
H Kitagawa et al.
NEUROPSYCHOPHARMACOLOGY (2003)
Selective cognitive dysfunction in acetylcholine M-1 muscarinic receptor mutant mice
SG Anagnostaras et al.
NATURE NEUROSCIENCE (2003)
In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia
TJ Raedler et al.
AMERICAN JOURNAL OF PSYCHIATRY (2003)
Dementia rating and nicotinic receptor expression in the prefrontal cortex in schizophrenia
CM Martin-Ruiz et al.
BIOLOGICAL PSYCHIATRY (2003)
Association of muscarinic M1 receptor genetic polymorphisms with psychiatric symptoms and cognitive function in schizophrenic patients
DL Liao et al.
NEUROPSYCHOBIOLOGY (2003)
Dysregulated hippocampal acetylcholine neurotransmission and impaired cognition in M2, M4 and M2/M4 muscarinic receptor knockout mice
ET Tzavaral et al.
MOLECULAR PSYCHIATRY (2003)
Nicotinic receptor subtypes and cognitive function
ED Levin
JOURNAL OF NEUROBIOLOGY (2002)
Association of promoter variants in the α7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia
S Leonard et al.
ARCHIVES OF GENERAL PSYCHIATRY (2002)
Longitudinal follow-up of neurochemical changes during the first year of antipsychotic treatment in schizophrenia patients with minimal previous medication exposure
JR Bustillo et al.
SCHIZOPHRENIA RESEARCH (2002)
Deletion of the M5 muscarinic acetylcholine receptor attenuates morphine reinforcement and withdrawal but not morphine analgesia
AS Basile et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Measuring nicotinic receptors with characteristics of α4β2, α3β2 and α3β4 subtypes in rat tissues by autoradiography
DC Perry et al.
JOURNAL OF NEUROCHEMISTRY (2002)
Effects of NMDA receptor antagonists: Implications for the pathophysiology of schizophrenia
JH Krystal et al.
ARCHIVES OF GENERAL PSYCHIATRY (2002)
Initiation of daily smoking and nicotine dependence in schizophrenia and mood disorders
J de Leon et al.
SCHIZOPHRENIA RESEARCH (2002)
Discovery of an ectopic activation site on the M1 muscarinic receptor
TA Spalding et al.
MOLECULAR PHARMACOLOGY (2002)
Brain-selective stimulation of nicotinic receptors by TC-1734 enhances ACh transmission from frontoparietal cortex and memory in rodents
MC Obinu et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2002)
Intracellular Ca2+ signals evoked by stimulation of nicotinic acetylcholine receptors in SH-SY5Y cells:: contribution of voltage-operated Ca2+ channels and Ca2+ stores
FA Dajas-Bailador et al.
JOURNAL OF NEUROCHEMISTRY (2002)
Synaptic mechanisms underlie nicotine-induced excitability of brain reward areas
HD Mansvelder et al.
NEURON (2002)
Decreased muscarinic(1) receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia
B Dean et al.
MOLECULAR PSYCHIATRY (2002)
Hyperactivity, elevated dopaminergic transmission, and response to amphetamine in M1 muscarinic acetylcholine receptor-deficient mice
DJ Gerber et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Cholinergic dilation of cerebral blood vessels is abolished in M5 muscarinic acetylcholine receptor knockout mice
M Yamada et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
SCH 57790, a selective muscarinic M2 receptor antagonist, releases acetylcholine and produces cognitive enhancement in laboratory animals
GJ Carey et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2001)
Intragastric DMXB-A, an α7 nicotinic agonist, improves deficient sensory inhibition in DBA/2 mice
JK Simosky et al.
BIOLOGICAL PSYCHIATRY (2001)
Timing and location of nicotinic activity enhances or depresses hippocampal synaptic plasticity
D Ji et al.
NEURON (2001)
Laminar distribution of nicotinic receptor subtypes in cortical regions in schizophrenia
A Marutle et al.
JOURNAL OF CHEMICAL NEUROANATOMY (2001)
Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: A study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment
JM Crook et al.
AMERICAN JOURNAL OF PSYCHIATRY (2001)
The muscarinic agonist xanomeline increases monoamine release and immediate early gene expression in the rat prefrontal cortex
KW Perry et al.
BIOLOGICAL PSYCHIATRY (2001)
Mice lacking the M3 muscarinic acetylcholine receptor are hypophagic and lean
M Yamada et al.
NATURE (2001)
Physostigmine and cognition in schizotypal personality disorder
RM Kirrane et al.
SCHIZOPHRENIA RESEARCH (2001)
Effect of subtype selective nicotinic compounds on attention as assessed by the five-choice serial reaction time task
AJ Grottick et al.
BEHAVIOURAL BRAIN RESEARCH (2000)
(-)-spiro[1-azabicyclo[2.2.2]octane-3,5′-oxazolidin-2′-one], a conformationally restricted analogue of acetylcholine, is a highly selective full agonist at the α7 nicotinic acetylcholine receptor
G Mullen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)
Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia
CR Breese et al.
NEUROPSYCHOPHARMACOLOGY (2000)
Decreased muscarinic receptor binding in subjects with schizophrenia: A study of the human hippocampal formation
JM Crook et al.
BIOLOGICAL PSYCHIATRY (2000)
Long-term potentiation of excitatory inputs to brain reward areas by nicotine
HD Mansvelder et al.
NEURON (2000)
Xanomeline, an M1/M4 preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice
HE Shannon et al.
SCHIZOPHRENIA RESEARCH (2000)
Characterisation of the effects of nicotine in the five-choice serial reaction time task in rats: antagonist studies
A Blondel et al.
PSYCHOPHARMACOLOGY (2000)
Localization of M2 muscarinic acetylcholine receptor protein in cholinergic and non-cholinergic terminals in rat hippocampus
ST Rouse et al.
NEUROSCIENCE LETTERS (2000)
Presynaptic nicotinic receptors modulating dopamine release in the rat striatum
S Wonnacott et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2000)
Share Paper
